U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H36F3NO4
Molecular Weight 555.6277
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADOMEGLIVANT

SMILES

CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C3=CC=C(C=C3)C(C)(C)C

InChI

InChIKey=FASLTMSUPQDLIB-MHZLTWQESA-N
InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1

HIDE SMILES / InChI
Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. Adomeglivant lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Adomeglivant had been in phase II clinical trials by Eli Lilly for the treatment of type 2 diabetes mellitus. However, this research has been discontinued.

Originator

Curator's Comment: # Eli Lilly

Approval Year

PubMed

PubMed

TitleDatePubMed
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
2016 Jul
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
2017 Nov
Patents

Patents

Sample Use Guides

Type 2 Diabetes Mellitus: single daily dose of 20 milligrams (mg) Adomeglivant (LY2409021) administered orally in 1 of 2 treatment periods.
Route of Administration: Oral
Adomeglivant (LY2409021) was identified as a potent and selective antagonist that inhibits the human glucagon receptor (hGCGR) with a Ki of 6.66 +/- 0.64 nM and the mouse GCGR with a Ki of 75.3 +/-11.4 nM.
Name Type Language
ADOMEGLIVANT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ADOMEGLIVANT, (-)-
Common Name English
.BETA.-ALANINE, N-(4-((1S)-1-((4'-(1,1-DIMETHYLETHYL)-2,6-DIMETHYL(1,1'-BIPHENYL)-4-YL)OXY)-4,4,4-TRIFLUOROBUTYL)BENZOYL)-
Systematic Name English
ADOMEGLIVANT [USAN]
Common Name English
Adomeglivant [WHO-DD]
Common Name English
3-(4-((1S)-1-((4'-TERT-BUTYL-2,6-DIMETHYLBIPHENYL-4-YL)OXY)-4,4,4- TRIFLUOROBUTYL)BENZAMIDO)PROPANOIC ACID
Systematic Name English
LY-2409021
Code English
LY2409021
Code English
adomeglivant [INN]
Common Name English
Code System Code Type Description
SMS_ID
100000174616
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
DRUG BANK
DB11704
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
CAS
1488363-78-5
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
USAN
BC-87
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
CAS
872260-20-3
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
SUPERSEDED
NCI_THESAURUS
C166989
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
INN
10202
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
FDA UNII
74Z5ZL2KVG
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
PUBCHEM
91933867
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707351
Created by admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
PRIMARY